Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients

Biomarker Research

Ulf Yrlid¹  Tobias Hofving²  Aylin Alkan²  Eva Angenete³ 

[1] Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Region Västra Götaland, Department of Surgery, SSORG - Scandinavian Surgical Outcomes Research Group, Sahlgrenska University Hospital, Gothenburg, Sweden;

关键词: Rectal cancer;    Biomarkers;    Neoadjuvant therapy;    Microenvironment;    Patient-derived xenografts;    Patient-derived organoids;   

DOI  :  10.1186/s40364-021-00313-9

来源: Springer

【 摘 要 】

Rectal cancer constitutes approximately one-third of all colorectal cancers and contributes to considerable mortality globally. In contrast to colon cancer, the standard treatment for localized rectal cancer often involves neoadjuvant chemoradiotherapy. Tumour response rates to treatment show substantial inter-patient heterogeneity, indicating a need for treatment stratification. Consequently researchers have attempted to establish new means for predicting tumour response in order to assist in treatment decisions. In this review we have summarized published findings regarding potential biomarkers to predict neoadjuvant treatment response for rectal cancer tumours. In addition, we describe cell-based models that can be utilized both for treatment prediction and for studying the complex mechanisms involved.

【 授权许可】

CC BY